Navigation Links
Major Repligen (Nasdaq: RGEN) Shareholder Files Amended 13D

CHICAGO, March 5, 2012 /PRNewswire/ --

Washington, D.C. 20549

Schedule 13DUnder the Securities Exchange Act of 1934
(Amendment No. 7)*REPLIGEN CORP
(Name of Issuer)Common Stock, Par Value $0.01 Per Share
(Title of Class of Securities)759916 10 9
(CUSIP Number)

Barry L. Fischer
Thompson Coburn LLP
55 East Monroe Street
Suite 3700
Chicago, IL 60603
(312) 346-75
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)March 5, 2012
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), (f) or (g), check the following box .

Note:  Schedules filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits.  See Rule 13d-7(b) for other parties to whom copies are being sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).1NAMES OF REPORTING PERSON



Individual Retirement Accounts for the benefit of Ronald L. Chez and Ronald L. Chez Individually2CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)  (b)


 4SOURCE OF FUNDS (See Instructions)








9.2%(1)14TYPE OF REPORTING PERSON (See Instructions)





Based upon 30,714,757 shares of the Issuer's common stock issued and outstanding as of October 31, 2011, as reported on the Issuer's Form 10-Q for the quarterly period ended September 30, 2011.Pursuant to Rule 13d-2 of Regulation 13D-G of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended, the undersigned, Ronald L. Chez (the "Reporting Person") hereby amends his statement on Schedule 13D dated January 30, 2007, as amended by Amendment No. 1 to Schedule 13D dated July 13, 2007; Amendment No. 2 to Schedule 13D dated October 20, 2008; Amendment No. 3 to Schedule 13D dated June 20, 2011; Amendment No. 4 to Schedule 13D dated July 13, 2011; and Amendment No. 5 to Schedule 13D dated August 15, 2011; and Amendment No. 6 to Schedule 13D dated January 25, 2012
(collectively, the "Schedule 13D").  This Statement constitutes Amendment No. 7 to the Schedule 13D.  Unless otherwise indicated herein, there are no material changes to the information set forth in the Schedule 13D.

Item 4.
Purpose of Transaction
is hereby amended by adding thereto the following:On March 5, 2012, the Reporting Person sent an e-mail to Karen Dawes, Co-Chairperson of the Board of the Issuer.  The contents of the e-mail are attached as Annex A to this Amendment No. 7 to Schedule 13D.

Item 5.
Interest in Securities of the Issuer
is hereby amended and restated in its entirety as follows:(a)
The aggregate number of shares of the Stock owned beneficially by the Reporting Person is 2,815,631 (the "Shares") constituting approximately 9.2% of the outstanding shares of the Stock.
The percentages in this Item  5(a) are based upon 30,714,757 shares of the Issuer's common stock issued and outstanding as of October 31, 2011, as reported on the Issuer's Form 10-Q for the fiscal quarter ended September 30, 2011. 

The Reporting Person has the sole power (and no shared power) to vote or dispose of or direct the disposition of Shares owned by such Reporting Person.

During the sixty (60) days prior to the filing of this Amendment to this Schedule 13D, the Reporting Person has made no transactions in the Shares of the Issuer:

Not applicable.

Not applicable.

SIGNATUREAfter reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated as of March 5, 2012




___/s/ Barry L. Fischer_______________

Barry L. Fischer,

attorney-in-fact for Ronald L. Chez 


 Annex A

March 5, 2012

VIA E-Mail
Karen Dawes
Repligen Corporation

Ms. Dawes:

Thank you for your e-mail of February 27th, where you indicated that you thought we had a constructive discussion in Boston, and indicated that I should submit any director candidates to Repligen's Nominating and Corporate Governance Committee.

I would take issue with regard to the quality of the meeting, considering that I flew from Chicago to Boston to attend the meeting in person, only to be informed upon my arrival that the meeting would be of very limited duration.

As I have repeatedly stated, I am simply trying to make sure that the voice of the shareholders of Repligen is heard at the board level, and that Repligen's policies are modified in matters of compensation, stockholder ownership of board members and officers, etc. to enhance the alignment of the Board's interests with those of its shareholders. 

As for submitting candidates to the Nominating and Governing Committee, it should not be necessary for me to go through that procedure. Considering my extensive holdings in Repligen, obviously it is in my interest that any candidate I would propose will have the qualities, skills and characteristics to serve as a constructive director.  Frankly, the non-transparent nature of the committee's deliberations and the short window for providing information to the committee strikes me as ways Repligen is seeking to entrench its existing Directors and officers.  The deadline to provide candidates in my case serves to limit my ability to select the best candidate(s).  I would therefore ask that the deadline for my submission be extended for 90 days, or waived entirety.  I request that the Committee pledges to work with me in good faith so that the person or persons I select are recommended by the Committee.  Please respond by March, 15 2012 to my proposal.

I have been a patient, long-term investor and supporter of Repligen.  As you know, I own nearly 10% of Repligen and my discussions with several other substantial holders of stock indicate broad support for additional involvement of shareholders in the Board, including new board members.  As we have repeatedly discussed, I would like to work collaboratively with the Board, and not at cross-purposes. However, I reserve my right under the Company's by-laws to take whatever action is permitted thereunder with respect to the nomination of any and all of Repligen's directors, including, without limitation, with respect to the nomination of and voting for directors, and the other actions regarding the matters discussed in this letter.

Your response by March 15, 2012 is appreciated.

Ronald L Chez


SOURCE Ronald L. Chez, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Job Cuts from Major Pharmaceutical Firms Results in Tougher Competition, Says Advance Recruitment
2. SCOLR Pharma, Inc. Launches Cutting Edge Nutritional Products at Major Retailers in 2012
3. GMH Ventures Acquires Majority Ownership in Dynamic Healthcare Services, Leading Provider of Medical Equipment and Respiratory Therapy Products and Services
4. CME LLC Announces the Launch of the CME Activity Advances in the Management of Major Depressive Disorders
5. Brainlab ExacTrac® System Achieves Major Sales Milestone
6. Neuralstems NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib
7. Unity Management Group, Inc. Announces Its Initial Sale of the PZ UNO Tablet Press to a Major Pharmaceutical Company for $500,000
8. Ferring Pharmaceuticals To Develop Major Corporate Center in Parsippany, New Jersey
9. Major Israeli Institution Selected to Lead Human Clinical Trials for Revolutionary Alpha Radiation Cancer Therapy
10. Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial
11. Scandal Exposed in Major Study of Autism and Mercury
Post Your Comments:
(Date:11/26/2015)... UTRECHT , Nederland, November 26, 2015 ... --> Een nieuwe aanpak combineert ... van gevorderde kanker. ... -->      (Photo: ... van het Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes ... titles work with any font, giving users limitless opportunities to stylize and create ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... more aggressive than those found on mammography, according to a study published online ... additional cancers not seen on mammography may necessitate a change in treatment. , ...
(Date:11/25/2015)... MN (PRWEB) , ... November 25, 2015 , ... Finnleo, ... through Christmas Eve on several models of traditional and far-infrared saunas. , ... Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only European ...
(Date:11/25/2015)... ... , ... Dr. John Pierce, Medical Director at the Ageless Forever clinic in ... Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 offers ... for surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a home-use ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is ... One Beat ” campaign. The partnership between the two groups began in 2014 with ... International’s cause. , MAP International was founded in 1954 and is an international Christian-based ...
Breaking Medicine News(10 mins):